Dr Reddys Laboratories (RDY) Net Cash Flow Growth (5y) (2014 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Net Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.72 Bn | 39.07 Bn | 2.15 Bn |
| 2 | Viatris | 19.14 Bn | 18.26 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.89 Bn | 9.71 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.34 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 494.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 994.43 Mn | 704.31 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 399.34 Mn | 358.09 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.33 Mn | 178.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.57% |
| Mar 31, 2026 | -11.69% |
| Dec 31, 2025 | 68.42% |
| Sep 30, 2025 | 25.26% |
| Jun 30, 2025 | -33.00% |
| Mar 31, 2025 | -101.20% |
| Dec 31, 2024 | 21.21% |
| Sep 30, 2024 | 42.22% |
| Jun 30, 2024 | -60.94% |
| Mar 31, 2024 | -20.89% |
| Dec 31, 2023 | -22.00% |
| Sep 30, 2023 | 29.85% |
| Jun 30, 2023 | 40.25% |
| Mar 31, 2023 | -20.75% |
| Dec 31, 2022 | -34.42% |
| Sep 30, 2022 | 46.23% |
| Jun 30, 2022 | -52.64% |
| Mar 31, 2022 | -46.47% |
| Dec 31, 2021 | 15.41% |
| Sep 30, 2021 | 15.80% |